Zacks Investment Research downgraded shares of Selecta Biosciences (NASDAQ:SELB) from a buy rating to a hold rating in a report published on Thursday.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
A number of other equities analysts also recently issued reports on SELB. UBS Group set a $6.00 price objective on Selecta Biosciences and gave the stock a hold rating in a report on Friday, November 9th. Mizuho restated a buy rating and set a $30.00 price target on shares of Selecta Biosciences in a report on Wednesday, October 17th. Stifel Nicolaus assumed coverage on Selecta Biosciences in a report on Friday, September 14th. They set a buy rating and a $24.00 price target for the company. BidaskClub downgraded Selecta Biosciences from a hold rating to a sell rating in a report on Saturday, October 27th. Finally, Janney Montgomery Scott restated a buy rating on shares of Selecta Biosciences in a report on Tuesday, October 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $23.21.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08. As a group, analysts expect that Selecta Biosciences will post -2.92 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in shares of Selecta Biosciences during the third quarter valued at $196,000. MetLife Investment Advisors LLC purchased a new stake in shares of Selecta Biosciences during the third quarter valued at $225,000. Rhumbline Advisers boosted its position in shares of Selecta Biosciences by 43.7% during the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after buying an additional 5,103 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Selecta Biosciences during the third quarter valued at $363,000. Finally, Marshall Wace LLP purchased a new stake in shares of Selecta Biosciences during the third quarter valued at $396,000. Hedge funds and other institutional investors own 51.04% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Article: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.